[Current management of myelodysplastic syndromes]. / Prise en charge actuelle des syndromes myélodysplasiques.
Rev Med Suisse
; 7(306): 1634, 1636-8, 1640-3, 2011 Aug 31.
Article
en Fr
| MEDLINE
| ID: mdl-21972730
ABSTRACT
Treatment of myelodysplastic syndromes (MDS) has improved in recent years with better results of allogeneic stem cell therapy (SCT), the advent of new therapeutic options such as hypomethylating agents and lenalidomide, the introduction of iron chelation therapy and the implication of erythropoietic stimulating agents in the treatment of anemia. In this review, we summarize the different diagnostic and prognostic criteria and outline the different treatment options we have in 2011.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Síndromes Mielodisplásicos
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
Fr
Revista:
Rev Med Suisse
Asunto de la revista:
MEDICINA
Año:
2011
Tipo del documento:
Article
País de afiliación:
Bélgica